Karyopharm Therapeutics Inc
KPTI
View Detailed Chart
6.260USD
+0.170+2.79%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
54.47MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.79%
5 Days
-3.99%
1 Month
-14.83%
6 Months
+55.33%
Year to Date
-14.95%
1 Year
-36.48%
View Detailed Chart
TradingKey Stock Score of Karyopharm Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Karyopharm Therapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 95 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.40.In the medium term, the stock price is expected to trend up.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Karyopharm Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Karyopharm Therapeutics Inc Highlights
StrengthsRisks
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Overvalued
The company’s latest PE is -0.43, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 6.66M shares, increasing 14.79% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 559.62K shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
15.400
Target Price
+152.87%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Karyopharm Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Karyopharm Therapeutics Inc Info
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Ticker SymbolKPTI
CompanyKaryopharm Therapeutics Inc
CEOPaulson (Richard A)
Websitehttps://karyopharm.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68657.870
-1312.260 (-1.88%)
282.580
+22.390 (+8.61%)
2037.700
-14.030 (-0.68%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
